Sun Pharma Boosts Expansion Drive with Rs 3,000-Crore Manufacturing Project in Madhya Pradesh
The development reflects the growing momentum in India’s pharmaceutical sector, as companies invest in advanced infrastructure to strengthen global competitiveness.
- By PTI
- New Delhi
- Dec 03, 2025
Sun Pharmaceutical Industries is set to significantly ramp up its manufacturing capacity, with its wholly owned subsidiary, Sun Pharma Laboratories Ltd, approving a major investment to establish a new greenfield plant in Madhya Pradesh. The company announced that it will invest ₹3,000 crore to develop a formulations manufacturing facility in the state.
The decision, cleared by the subsidiary’s board, marks a strategic expansion aimed at strengthening Sun Pharma’s production network and meeting growing market demand. The proposed facility aligns with the company’s broader plans to scale operations and reinforce its presence across key regions.
This investment move follows earlier discussions held during a state investment summit, where Madhya Pradesh highlighted its potential as a pharmaceutical manufacturing hub. The new plant is expected to support high-volume drug production and contribute to industrial growth within the region.
Following the announcement, Sun Pharma’s stock saw a slight rise, closing 0.43% higher at ₹1,805.70 on the BSE. Analysts see the project as a positive indicator of the company’s long-term growth strategy, with potential benefits including increased employment and enhanced local supply chain activity.
The development reflects the growing momentum in India’s pharmaceutical sector, as companies invest in advanced infrastructure to strengthen global competitiveness.